Live feed16:15:00·998dPRReleasevia QuantisnowNANOBIOTIX Announces Oral Presentation of Final Results From a Phase 1 Dose Expansion Study Evaluating NBTXR3 in Head and Neck Cancer at the 65th Annual Meeting of the American Society for Radiation OncologyByQuantisnow·Wall Street's wire, on your screen.NBTX· Nanobiotix S.A.Health Care
